Four venture capital firms have raised more than $1bn in new money for life science and health care investments, which could be divided among a large number of biotechnology companies if a recent trend toward smaller funding rounds continues for US and EU firms.
There's been some concern during the past few record-breaking years of biotech venture capital financing about the decline in seed...